![Nascent Group Points to a Way To Validate, Pay for Genomic Tests](https://cdn.cancerletter.com/media/2024/01/29025555/41-18-MED-C.jpg)
![Nascent Group Points to a Way To Validate, Pay for Genomic Tests](https://cdn.cancerletter.com/media/2024/01/29025555/41-18-MED-C.jpg)
Cover Story
How is this for a plan:
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Drugs & Targets
Trending Stories
- Lei Zheng named executive director of Mays Cancer Center
- Infections are a major cause of death in patients treated with CAR T-cell therapy
Meta-analysis focused on causes of death, excluding relapse, recurrence - In 1971, Chris Lundy had minute odds of survival. He is now the longest living BMT recipient at the Hutch
- Murphy, McKay, Nodora, Ballantyne, Stupack named associate directors at UCSD Moores
- How Beth Carner went from six weeks left to live with stage 4 colon cancer to complete remission
- NCI’s new chief data scientist Warren Kibbe tells us about efforts to get “AI-ready”
“All research now involves data science at some level.”